Loopbaan van Gregory S. Moss
Eerdere bekende functies van Gregory S. Moss
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
KADMON HOLDINGS, INC. | Compliance Officer | 30-08-2019 | 01-06-2022 |
Algemeen Adviseur | 30-08-2019 | 01-06-2022 | |
Corporate Officer/Principal | 01-01-2015 | 30-08-2019 | |
Bedrijfssecretaris | 30-08-2019 | 01-06-2022 | |
MEIRAGTX HOLDINGS PLC | Directeur/Bestuurslid | 01-05-2018 | 19-06-2019 |
MeiraGTx Ltd.
MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Compliance Officer | 01-04-2015 | 01-12-2016 |
Algemeen Adviseur | 01-04-2015 | 01-12-2016 |
Opleiding van Gregory S. Moss
Macquarie University | Graduate Degree |
Statistieken
Internationaal
Kaaimaneilanden | 2 |
Verenigde Staten | 2 |
Verenigd Koninkrijk | 2 |
Operationeel
Compliance Officer | 2 |
General Counsel | 2 |
Director/Board Member | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
MEIRAGTX HOLDINGS PLC | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
MeiraGTx Ltd.
MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Gregory S. Moss
- Ervaring